MedWatch

Novo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four years

Few weeks into its launch, Novo Nordisk's new obesity treatment Wegovy is in high demand in the US, especially compared with the older drug Saxenda. Overall, Novo Nordisk's obesity business has had a strong second quarter, according to report.

Novo Nordisk Executive Vice President, Head of North America Operations, Doug Langa | Photo: Novo Nordisk / PR

Novo Nordisk's new obesity drug Wegovy certainly seems to have gotten off to a great start in the US following its approval from the US Food and Drug Administration (FDA) in early June.

Over the course of the first five weeks, more than 8,000 prescriptions have been issued for the new obesity drug, which is based around the GLP-1 analog semaglutide. This is a significantly faster development than what Novo Nordisk's other drug Saxenda went through, which was launched in 2015. It is based on the substance liraglutide, which is a predecessor to semaglutide.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs